Description du projet
Un système d’administration de médicaments à base d’albumine pour l’ostéoarthrite
Le traitement de l’ostéoarthrite , une maladie auto-immune, est principalement symptomatique; l’administration intra-articulaire (IA) de corticostéroïdes libres et d’acide hyaluronique étant les meilleures options disponibles. Cependant, la clairance rapide de ces molécules injectées depuis l’articulation après l’administration d’IA nécessite de multiples injections et rend l’administration de ces molécules peu pratique et peu efficace. Pour remédier à cette limitation, les scientifiques du projet IA-NANO, financé par l’UE, proposent de développer des particules d’albumine chargées de célécoxib, un anti-inflammatoire non stéroïdien. Ce système d’administration à action prolongée est biocompatible et biodégradable et devrait permettre une libération contrôlée du médicament dans l’articulation enflammée, réduisant ainsi le nombre d’injections de médicament libre et surmontant la toxicité systémique.
Objectif
Osteoarthritis (OA) is the most common chronic condition of the joints and is predicted to become the fourth largest cause of disability in the world by 2020. Its complete mechanism is yet to be deciphered. Though it is not curable, several medications are prescribed to manage the symptomatic OA, of which the oral and topical medications have shortcomings and the better option is the intra-articular (IA) delivery of free corticosteroids and hyaluronic acid. However, IA delivery is challenging due to the rapid clearance of the free injected molecules from the joint space and outcomes are suboptimal in terms of efficacy and a need for repeated injections. Our objective therefore is to load a candidate drug in a long-acting delivery system and inject it directly into the inflamed knee of a rat model of OA, following in vitro bioassay screening in primary human synoviocytes. Thus, in this project, we propose to develop non-toxic, biocompatible and biodegradable albumin particles loaded with the non-steroidal anti-inflammatory cyclooxygenase-2 inhibitor, celecoxib. This method is expected to reduce the side-effects associated with oral administration of celecoxib. In addition, it will also increase the drug local concentration in the joint and the controlled release of the drug will lead to reduction of inflammatory biomarkers in joints. The project is in line with the EU’s Horizon 2020 Programme focus area - Health, Demographic Change and Wellbeing and UN Sustainable Development goal - Good Health and Well-Being. It will be carried out by the researcher and supervisors who are experts in DDSs development, OA therapy and translational pharmaceutics. Both the researcher and the host are expected to benefit in this collaboration and the researcher will gain experience that will increase her future employability. The project will have great societal impact and commercial potential and will also help increase Europe’s position as the leading source of cutting-edge research.
Champ scientifique
Programme(s)
Régime de financement
MSCA-IF-EF-ST - Standard EFCoordinateur
4 Dublin
Irlande